• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

霉酚酸和他克莫司对肾移植后感染性并发症发生率的影响。

Effect of mycophenolic acid and tacrolimus on the incidence of infectious complications after kidney transplantation.

机构信息

Department of Surgery and Transplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin 03601, Slovakia.

Department of Surgery and Transplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin 03601, Slovakia.

出版信息

Int Immunopharmacol. 2021 Sep;98:107908. doi: 10.1016/j.intimp.2021.107908. Epub 2021 Jun 25.

DOI:10.1016/j.intimp.2021.107908
PMID:34182244
Abstract

INTRODUCTION

Infectious complications remain a common cause of mortality after kidney transplantation (KTx). Goal of effective immunosuppressive treatment (IS) must be balanced between decreasing incidence of acute kidney rejection (AKR) and avoiding the incidence of infections, at the same time.

MATERIALS AND METHODS

The aim of our analysis was to identify the risk of fixed daily dose (DD) of mycophenolic acid (MPA) and levels of tacrolimus (TAC) in the development of a single, recurrent infection and AKR after KTx.

RESULTS

Our analysis consisted of 100 patients after KTx (66 males, 34 females). MPA DD > 1080 mg was a risk factor (RF) for recurrent infection in general (OR 1.2964;P = 0.0277), for recurrent bacterial infection from 1 to 6 month (OR 1.2674;P = 0.0151), recurrent bacterial infection (OR 1.2574;P = 0.0436), single viral infection (OR 1.2640;P = 0.0398) from 6-12 month after KTx. MPA DD > 1080 mg and levels of TAC above recommended levels were not independent RF for the incidence of the infection.

CONCLUSION

MPA DD > 1080 mg as a RF for recurrent infection starting in the 1 month after KTx with significant association between the incidence of infections and MPA DD and TAC levels, without increased risk of AKR. In the centers with fixed dosing of IS, this can lead to lowering the risk of infections by decreasing MPA DD 1 month after KTx without increasing risk of infections.

摘要

简介

感染并发症仍然是肾移植(KTx)后死亡的常见原因。有效的免疫抑制治疗(IS)的目标必须在降低急性肾排斥(AKR)的发生率和避免感染的发生率之间取得平衡。

材料和方法

我们分析的目的是确定霉酚酸(MPA)固定日剂量(DD)和他克莫司(TAC)水平在 KTx 后单次、复发性感染和 AKR 发展中的风险。

结果

我们的分析包括 100 名 KTx 后的患者(66 名男性,34 名女性)。MPA DD>1080mg 是一般复发性感染的危险因素(OR 1.2964;P=0.0277),1-6 个月复发性细菌感染(OR 1.2674;P=0.0151),复发性细菌感染(OR 1.2574;P=0.0436),6-12 个月后单发性病毒感染(OR 1.2640;P=0.0398)。MPA DD>1080mg 和 TAC 水平高于推荐水平不是感染发生率的独立危险因素。

结论

MPA DD>1080mg 是 KTx 后 1 个月复发性感染的危险因素,感染的发生率与 MPA DD 和 TAC 水平之间存在显著关联,而 AKR 的风险没有增加。在采用固定剂量 IS 的中心,这可以通过在 KTx 后 1 个月降低 MPA DD 来降低感染风险,而不会增加感染风险。

相似文献

1
Effect of mycophenolic acid and tacrolimus on the incidence of infectious complications after kidney transplantation.霉酚酸和他克莫司对肾移植后感染性并发症发生率的影响。
Int Immunopharmacol. 2021 Sep;98:107908. doi: 10.1016/j.intimp.2021.107908. Epub 2021 Jun 25.
2
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.一项开放性、随机试验表明,依维莫司联合他克莫司或环孢素与标准免疫抑制方案在肾移植初治患者中的疗效相当。
Kidney Int. 2019 Jul;96(1):231-244. doi: 10.1016/j.kint.2019.01.041. Epub 2019 Feb 27.
3
Early Immunosuppressive Exposure of Enteric-Coated-Mycophenolate Sodium Plus Tacrolimus Associated with Acute Rejection in Expanded Criteria Donor Kidney Transplantation.麦考酚钠肠溶片联合他克莫司的早期免疫抑制治疗与扩展标准供肾移植术后急性排斥反应的关系。
Chin Med J (Engl). 2018 Jun 5;131(11):1302-1307. doi: 10.4103/0366-6999.232797.
4
Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients.霉酚酸谷浓度和剂量与肾移植受者的血液学异常有关,但与排斥无关。
J Korean Med Sci. 2020 Jun 22;35(24):e185. doi: 10.3346/jkms.2020.35.e185.
5
Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids.在接受他克莫司和皮质类固醇治疗的肾移植受者中比较硫唑嘌呤和霉酚酸酯的安全性概况。
Transpl Infect Dis. 2013 Aug;15(4):369-78. doi: 10.1111/tid.12095. Epub 2013 May 22.
6
Limits to intensified mycophenolate mofetil dosing in kidney transplantation.在肾移植中,霉酚酸酯强化剂量存在限制。
Ther Drug Monit. 2012 Dec;34(6):736-8. doi: 10.1097/FTD.0b013e31826d7bfa.
7
Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.减少霉酚酸剂量是否会影响疗效,而与他克莫司暴露水平无关?来自霉酚酸肾脏移植(MORE)注册研究的前瞻性数据分析。
Clin Transplant. 2013 Jan-Feb;27(1):15-24. doi: 10.1111/j.1399-0012.2012.01694.x. Epub 2012 Aug 2.
8
Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.接受抢先治疗的肾移植受者在第一年急性排斥反应治疗后巨细胞病毒感染的发生率及相关危险因素。
Transpl Infect Dis. 2019 Dec;21(6):e13106. doi: 10.1111/tid.13106. Epub 2019 Oct 29.
9
Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.肾胰联合移植后从他克莫司-霉酚酸酯转换为他克莫司-mTOR 免疫抑制可降低 BK 和 CMV 病毒血症的发生率。
Clin Transplant. 2018 Jun;32(6):e13265. doi: 10.1111/ctr.13265. Epub 2018 May 12.
10
Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.在致敏肾移植受者中使用新型 mTOR 抑制剂:临床实践经验。
Transplantation. 2020 Aug;104(8):1686-1694. doi: 10.1097/TP.0000000000003021.

引用本文的文献

1
Effect of Different Induction Immunosuppression on the Incidence of Infectious Complications after Kidney Transplantation-Single Center Study.不同诱导免疫抑制对肾移植术后感染并发症发生率的影响——单中心研究
J Clin Med. 2024 Apr 9;13(8):2162. doi: 10.3390/jcm13082162.